

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
63-165/s-3,s-5,s-6

MICROBIOLOGY REVIEW

CONSULTATIVE REVIEW TO HFD-600
MICROBIOLOGIST'S REVIEW OF SUPPLEMENT
DIVISION OF MEDICAL IMAGING, SURGICAL, AND DENTAL DRUG PRODUCTS
October 22, 1992

ANDA/Supplement Number: AADA 63-165 / S-005

Document Date: June 11, 1991

Name and Address of Applicant:

Adria Laboratories
Division of Erbamount, Inc.
P.O.Box 16529
Columbus, Ohio 43216-6529

Name of Drug: Adriamycin PFS® (doxorubicin hydrochloride injection, USP)

Supplement Provides For: Post-approval submission of fill validation information for the batch process (approved January 30, 1991; validation information for the process is also submitted in this same 6-11-91 submission. This fulfills the commitment contained in the applicant's January 11, 1990 (sic, applicant's letter) submission.

Pharmacological Category: cytotoxic anthracycline antibiotic

Dosage Form: Sterile solution in single-use vials (2 mg/mL) with rubber stopper and aluminum seal:

5 mL (10 mg) fill in 6 mL vial,
10 mL (20 mg) fill in 10 mL vial,
25 mL (50 mg) fill in 30 mL vial, and
100 mL (200 mg) fill in 100 mL vial (multidose).

Conclusions and Recommendations: Recommend approval of supplement for sterility assurance. See Review Notes below.

Signature: Carol K. Vincent 10-22-92

Carol K. Vincent, HFD-160

JVK 10/23/92

MAC 10/23/92

Page(s)

10

Contain Trade Secret,
Commercial/Confidential
Information and are not
releasable.

Micro Rev.

10/22/92

DIVISION OF CHEMISTRY I
OFFICE OF GENERIC DRUGS

Microbiologist's Review #2

11 May 1993

A. 1. AADA: 63-165/S-007

APPLICANT: Adria Laboratories
P.O. Box 16529
Columbus, Ohio 43216-6529

2. PRODUCT NAMES: Doxorubicin Hydrochloride Injection USP
Adriamycin PFSTM

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: SVP preservative-free solution for intravenous administration. Single-dose vials: 10 mg/5 mL in a 6 mL vial, 20 mg/10 mL in a 10 mL vial, 50 mg/25 mL in a 30 mL vial. Multiple-dose vial: 200 mg/100 mL in a 120 mL vial.

4. METHOD(S) OF STERILIZATION:
by

5. PRINCIPLE INDICATIONS: To produce regression of disseminated neoplastic diseases such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilm's tumor, neuroblastoma, sarcomas, breast & ovarian carcinoma, transitional bladder cell carcinoma, and various lymphomas.

6. PHARMACOLOGICAL CATEGORY: Antineoplastic antibiotic

B. 1. DATE OF INITIAL SUBMISSION: 3 November 1992

2. DATE OF AMENDMENT: 29 April 1993 Minor Amendment in response to the Agency's deficiency letter of 30 March 1993
Subject of this review

3. RELATED DOCUMENTS: NDA's 50-629 & 50-467 held by the applicant for manufacture of Adriamycin PFSTM and Adriamycin RDFTM, respectively
DMF's held by Italy for production of the raw drug substance
DMF held by The for closures

4. ASSIGNED FOR REVIEW: 10 May 1993

C. REMARKS: Three questions concerning the sterility assurance of the manufacturing rework procedure for the subject drug product (Doxorubicin Hydrochloride Injection USP) were communicated to the applicant via letter. The applicant's response to all three questions was adequate.

D. CONCLUSIONS: The submissions are therefore recommended for approval on the basis of sterility assurance. Specific comments are provided in "E. Review Notes".

Kenneth H. Muhvich 5/11/93

Kenneth H. Muhvich, Ph.D.

cc:

1

~~John Wolf~~ 5/12/93

Page(s) 2

Contain Trade Secret,
Commercial/Confidential
Information and are not
releasable.

Micro Rev. 2

5/12/93